The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial
Open accessAbstract
Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV.REP1) in patients with this disease.Methods In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV.REP1 (0·6-1·0×10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213.Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3·8 letters (SE 4·1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23·0 dB (SE 1·1) at baseline to 25·3 dB (1·3) after treatment (increase 2·3 dB [95% CI 0·8-3·8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1·7 [SE 1·0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0·82, p=0·04). By contrast, small non-significant reductions (p>0·05) were noted in the control eyes in both maximal sensitivity (-0·8 dB [1·5]) and mean sensitivity (-1·6 dB [0·9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector.Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning.Funding UK Department of Health and Wellcome Trust.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As a consequence, wild-type AAV-based gene therapies for ophthalmologic indications generally require relatively high doses and/or administration via subretinal injection, an invasive surgical procedure that requires detachment of photoreceptors from the RPE and reportedly results in transduction of <5% of the retinal surface. 25 – 27”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although adeno-associated viral (AAV) vector-mediated retinal gene therapies have demonstrated efficacy”
From Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina (2021) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, a recent phase I trial for choroideremia showed promising signs of efficacy.15”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [15]
The cited source says what the claim attributes to it.
In the citing paper
“A different approach to subretinal injection is a 'two-step ' injection with initiation of a small 'pre-bleb ' using balanced saline solution (BSS) followed by slow propagation of the bleb using the viral vector (MacLaren et al., 2014). A considerable advantage of two-step injection is that it allows bleb propagation at a lower injection pressure (Scruggs et al., 2022).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as MacLaren et al., 2014
In the citing paper
“Significant inflammation was also observed at 1 × 1011 vg in clinical trials for choroideremia.90,102”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [102]
In the citing paper
“Injection protocols dating to 2014 (30, 31) called for a 2-step procedure, which largely avoids causing a break in Bruch's membrane but does not completely eliminate the risk (20, 32).”
From Subretinal therapy: technological solutions to surgical and immunological challenges (2022) · cites this paper as [30]
In the citing paper
“while subretinal viral gene therapy has a favourable safety profile [300]”
From Bruch’s Membrane: A Key Consideration with Complement-Based Therapies for Age-Related Macular Degeneration (2023) · cites this paper as [300]
In the citing paper
“A phase I/II clinical trial of subretinal gene therapy using an AAV2 vector to deliver human REP1 to the outer retina has shown sustained preservation or improvement of visual acuity over 2 to 5 years in patients with advanced disease [MacLaren 2014, Xue 2018].”
From Correcting visual loss by genetics and prosthetics (2020) · cites this paper as MacLaren 2014
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
LeWitt, P. A., Rezai, A. R., Leehey, M. A., Ojemann, S. G., Flaherty, A. W., Eskandar, E. N., Kostyk, S. K., Thomas, K., Sarkar, A., Siddiqui, M. S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70039-4 · Cited by 681
Self-citationJacobson, S. G. (2012) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.298 · Cited by 639
Sieving, P. A., Caruso, R. C., Tao, W., Coleman, H. R., Thompson, D. J. S., Fullmer, K. R., & Bush, R. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600236103 · Cited by 591
Cideciyan, A. V., Jacobson, S. G., Beltran, W. A., Sumaroka, A., Świder, M., Iwabe, S., Román, A. J., Olivares, M. B., Schwartz, S., Komáromy, A. M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218933110 · Cited by 441
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness
Bennett, J., Ashtari, M., Wellman, J., Marshall, K. A., Cyckowski, L. L., Chung, D. C., McCague, S., Pierce, E. A., Chen, Y., Bennicelli, J. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002865 · Cited by 395
Retinal degeneration in choroideremia: deficiency of rab geranylgeranyl transferase
Seabra, M. C., Brown, M. S., & Goldstein, J. L. (1993) · Science · doi:10.1126/science.8380507 · Cited by 337
Self-citationCloning of a gene that is rearranged in patients with choroideraemia
Cremers, F. P. M., van de Pol, D. J. R., van Kerkhoff, L. P. M., Wieringa, B., & Ropers, H.-H. (1990) · Nature · doi:10.1038/347674a0 · Cited by 333
Self-citationLoeb, J. E., Cordier, W. S., Harris, M. E., Weitzman, M. D., & Hope, T. J. (1999) · Human Gene Therapy · doi:10.1089/10430349950016942 · Cited by 279
Cited by
Sorted by citations
Items 101–200 of 795
Pharmacological approaches to retinitis pigmentosa: A laboratory perspective
Guadagni, V., Novelli, E., Piano, I., Gargini, C., & Strettoi, E. (2015) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2015.06.005 · Cited by 94
Retinal dystrophies, genomic applications in diagnosis and prospects for therapy.
Nash, B. M., Wright, D. C., Grigg, J., Bennetts, B., & Jamieson, R. V. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.03 · Cited by 96
Duebel, J., Marazova, K., & Sahel, J. (2015) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000140 · Cited by 95
PABPN1 gene therapy for oculopharyngeal muscular dystrophy
Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S., Córdova, G., Ferry, A., Strings, V. R., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., et al. (2017) · Nature Communications · doi:10.1038/ncomms14848 · Cited by 91
An AAV Dual Vector Strategy Ameliorates the Stargardt Phenotype in Adult Abca4 −/− Mice
McClements, M. E., Barnard, A. R., Singh, M. S., Charbel Issa, P., Jiang, Z., Radu, R. A., & MacLaren, R. E. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.156 · Cited by 92
Self-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.3278 · Cited by 92
Self-citationCremers, F. P. M., Boon, C. J. F., Bujakowska, K. M., & Zeitz, C. (2018) · Genes · doi:10.3390/genes9040215 · Cited by 99
Self-citationde Guimarães, T. A. C., Georgiou, M., Bainbridge, J. W., & Michaelides, M. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316195 · Cited by 94
Li, X., Salvia, S. L., Liang, Y., Adamiak, M., Kohlbrenner, E., Jeong, D., Chepurko, E., Ceholski, D. K., López-Gordo, E., Yoon, S., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063759 · Cited by 92
Silva, S. R. D., Barnard, A. R., Hughes, S., Tam, S. K. E., Martin, C. J., Singh, M. S., Barnea-Cramer, A. O., McClements, M. E., During, M. J., Peirson, S. N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1701589114 · Cited by 89
Self-citationGene therapy for inherited retinal and optic nerve degenerations
Moore, N. A., Morral, N., Ciulla, T. A., & Bracha, P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1389886 · Cited by 91
Treatment of ocular disorders by gene therapy
Solinís, M. Á., del Pozo-Rodríguez, A., Apaolaza, P. S., & Rodríguez-Gascón, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.12.022 · Cited by 88
Astuti, G., Bertelsen, M., Preising, M. N., Ajmal, M., Lorenz, B., Faradz, S. M., Qamar, R., Collin, R. W. J., Rosenberg, T., & Cremers, F. P. M. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.241 · Cited by 86
Self-citationRandomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy
Newman, N. J., Yu-Wai-Man, P., Subramanian, P. S., Moster, M. L., Wang, A.-G., Donahue, S. P., Leroy, B. P., Carelli, V., Biousse, V., Vignal-Clermont, C., et al. (2023) · Brain · doi:10.1093/brain/awac421 · Cited by 87
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease
Yang, Y., & Dunbar, H. (2021) · Ophthalmologica · doi:10.1159/000515148 · Cited by 93
Pellissier, L. P., Quinn, P. M., Alves, C. H., Vos, R. M., Klooster, J., Flannery, J. G., Heimel, J. A., & Wijnholds, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv062 · Cited by 86
Evaluating Efficiencies of Dual AAV Approaches for Retinal Targeting
Carvalho, L. S., Turunen, H. T., Wassmer, S. J., Luna-Velez, M. V., Xiao, R., Bennett, J., & Vandenberghe, L. H. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00503 · Cited by 86
New molecular therapies for the treatment of hearing loss
Ma, Y., Wise, A. K., Shepherd, R. K., & Richardson, R. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.003 · Cited by 86
Xue, K., Oldani, M., Jolly, J. K., Edwards, T. L., Groppe, M., Downes, S. M., & MacLaren, R. E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18364 · Cited by 83
Self-citationOptoretinography of individual human cone photoreceptors
Cooper, R. F., Brainard, D. H., & Morgan, J. I. W. (2020) · Optics Express · doi:10.1364/oe.409193 · Cited by 82
Gene therapy for retinal disease
McClements, M. E., & MacLaren, R. E. (2013) · Translational Research · doi:10.1016/j.trsl.2012.12.007 · Cited by 80
Self-citationAdvances in gene therapy for diseases of the eye
Petit, L., Khanna, H., & Punzo, C. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.040 · Cited by 82
Adeno-associated virus-mediated cancer gene therapy: Current status
Luo, J., Luo, Y., Sun, J., Zhou, Y., Zhang, Y., & Yang, X. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.10.045 · Cited by 85
The Spectrum of CHM Gene Mutations in Choroideremia and Their Relationship to Clinical Phenotype
Simunovic, M. P., Jolly, J. K., Xue, K., Edwards, T. L., Groppe, M., Downes, S. M., & MacLaren, R. E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-20230 · Cited by 79
Self-citationSanjurjo-Soriano, C., Erkilic, N., Baux, D., Mamaeva, D. V., Hamel, C., Meunier, I., Roux, A., & Kalatzis, V. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.016 · Cited by 82
Gene therapy for inherited retinal diseases
Nuzbrokh, Y., Ragi, S. D., & Tsang, S. H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4726 · Cited by 79
Gene Therapy and Stem Cell Transplantation in Retinal Disease: The New Frontier
MacLaren, R. E., Bennett, J., & Schwartz, S. D. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.06.041 · Cited by 79
Self-citationPennesi, M. E., Yang, P., Birch, D. G., Weng, C. Y., Moore, A. T., Iannaccone, A., Comander, J. I., Jayasundera, T., Chulay, J., Chulay, J., et al. (2022) · Ophthalmology Retina · doi:10.1016/j.oret.2022.06.013 · Cited by 71
Pawlyk, B. S., Bulgakov, O. V., Sun, X., Adamian, M., Shu, X., Smith, A. J., Berson, E. L., Ali, R. R., Khani, S. C., Wright, A. F., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.93 · Cited by 78
Zhu, X., Xu, J., Ling, G., & Zhang, P. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00386h · Cited by 79
Highly Efficient Delivery of Adeno-Associated Viral Vectors to the Primate Retina
Boye, S. L., Alexander, J. J., Witherspoon, C. D., Boye, S. L., Peterson, J. J., Clark, M. E., Sandefer, K. J., Girkin, C. A., Hauswirth, W. W., & Gamlin, P. D. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.085 · Cited by 81
Dolz‐Marco, R., Litts, K. M., Tan, A. C. S., Freund, K. B., & Curcio, C. A. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.03.043 · Cited by 78
Moosajee, M., Tracey‐White, D., Smart, M. J. K., Weetall, M. L., Torriano, S., Kalatzis, V., da Cruz, L., Coffey, P. J., Webster, A. R., & Welch, E. M. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw184 · Cited by 77
Self-citationrAAV-compatible MiniPromoters for restricted expression in the brain and eye
de Leeuw, C. N., Korecki, A. J., Berry, G. E., Hickmott, J. W., Lam, S. L., Lengyell, T. C., Bonaguro, R. J., Borretta, L. J., Chopra, V., Chou, A. Y., et al. (2016) · Molecular Brain · doi:10.1186/s13041-016-0232-4 · Cited by 76
Scalabrino, M. L., Boye, S. L., Fransen, K. M., Noel, J. M., Dyka, F. M., Min, S. H., Ruan, Q., de Leeuw, C. N., Simpson, E. M., Gregg, R. G., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv341 · Cited by 75
Optical Coherence Tomography Angiography in Choroideremia
Jain, N., Jia, Y., Gao, S. S., Zhang, X., Weleber, R. G., Huang, D., & Pennesi, M. E. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.0874 · Cited by 76
Liu, X., Tao, T., Zhao, L. Y., Li, G., & Yang, L. (2020) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13875 · Cited by 75
Visual Function and Central Retinal Structure in Choroideremia
Héon, E., Alabduljalil, T., McGuigan, D. B., Cideciyan, A. V., Li, S., Chen, S., & Jacobson, S. G. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18421 · Cited by 74
Surgical technique for subretinal gene therapy in humans with inherited retinal degeneration
Davis, J. L., Gregori, N. Z., MacLaren, R. E., & Lam, B. L. (2019) · Retina · doi:10.1097/iae.0000000000002609 · Cited by 72
Self-citationA systematic review of immunosuppressive protocols used in AAV gene therapy for monogenic disorders
Vrellaku, B., Hassan, I. S., Howitt, R., Webster, C. P., Harriss, E., McBlane, F., Betts, C., Schettini, J. L., Lion, M., Mindur, J. E., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.07.016 · Cited by 78
Khabou, H., Desrosiers, M., Winckler, C., Fouquet, S., Auregan, G., Bemelmans, A., Sahel, J., & Dalkara, D. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.26031 · Cited by 71
Heat Shock Proteins In The Retina: Focus On Hsp70 and Alpha Crystallins In Ganglion Cell Survival
Piri, N., Kwong, J. M. K., Gu, L., & Caprioli, J. (2016) · Progress in retinal and eye research · doi:10.1016/j.preteyeres.2016.03.001 · Cited by 72
Srivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 68
Ding, W. Y., Kuzmuk, V., Hunter, S., Lay, A. C., Hayes, B., Beesley, M., Rollason, R., Hurcombe, J., Barrington, F., Masson, C., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8226 · Cited by 75
A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration
Wu, Z., Hiriyanna, S., Qian, H., Mookherjee, S., Campos, M. M., Gao, C., Fariss, R. N., Sieving, P. A., Li, T., Colosi, P., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv134 · Cited by 71
Kumaran, N., Michaelides, M., Smith, A. J., Ali, R. R., & Bainbridge, J. W. (2018) · British Medical Bulletin · doi:10.1093/bmb/ldy005 · Cited by 74
Li, S., Datta, S., Brabbit, E., Love, Z., Woytowicz, V., Flattery, K., Capri, J., Yao, K., Wu, S., Imboden, M., et al. (2021) · Gene Therapy · doi:10.1038/s41434-020-0134-z · Cited by 68
Retinal gene delivery by adeno-associated virus (AAV) vectors: Strategies and applications
Schön, C., Biel, M., & Michalakis, S. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.01.009 · Cited by 72
Britten‐Jones, A. C., Jin, R., Gocuk, S. A., Cichello, E., O’Hare, F., Hickey, D. G., Edwards, T. L., & Ayton, L. N. (2021) · Genetics in Medicine · doi:10.1016/j.gim.2021.10.013 · Cited by 67
Gene Therapy in Inherited Retinal Diseases: An Update on Current State of the Art
Amato, A., Arrigo, A., Aragona, E., Manitto, M. P., Saladino, A., Bandello, F. M., & Parodi, M. B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.750586 · Cited by 68
Panel-Based Clinical Genetic Testing in 85 Children with Inherited Retinal Disease
Taylor, R. L., Parry, N. R. A., Barton, S., Campbell, C., Delaney, C. M., Ellingford, J. M., Hall, G., Hardcastle, C. L., Morarji, J., Nichol, E. J., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.02.005 · Cited by 67
Self-citationConsequences of Rab GTPase dysfunction in genetic or acquired human diseases
Banworth, M. J., & Li, G. (2017) · Small GTPases · doi:10.1080/21541248.2017.1397833 · Cited by 68
Changes in Retinal Sensitivity after Gene Therapy in Choroideremia
Fischer, M. D., Ochakovski, G. A., Beier, B., Seitz, I. P., Vaheb, Y., Kortuem, C., Reichel, F. F. L., Kuehlewein, L., Kahle, N. A., Peters, T., et al. (2020) · Retina · doi:10.1097/iae.0000000000002360 · Cited by 66
Self-citationJolly, J. K., Edwards, T. L., Moules, J., Groppe, M., Downes, S. M., & MacLaren, R. E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18362 · Cited by 66
Self-citationStem cells for investigation and treatment of inherited retinal disease
Tucker, B. A., Mullins, R. F., & Stone, E. M. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu124 · Cited by 65
Gene and cell‐based therapies for inherited retinal disorders: An update
Sengillo, J. D., Justus, S., Tsai, Y., Cabral, T., & Tsang, S. H. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31534 · Cited by 70
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 66
Ye, G.-J., Budzynski, E., Sonnentag, P., Nork, T. M., Miller, P. E., Sharma, A. K., Ver Hoeve, J. N., Smith, L. M., Arndt, T., Calcedo, R., et al. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.164 · Cited by 64
Suppression of Choroidal Neovascularization by AAV-Based Dual-Acting Antiangiogenic Gene Therapy
Askou, A. L., Alsing, S., Benckendorff, J. N. E., Holmgaard, A., Mikkelsen, J. G., Aagaard, L., Bek, T., & Corydon, T. J. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.01.012 · Cited by 64
Carvalho, L. S., Xiao, R., Wassmer, S. J., Langsdorf, A., Zinn, E., Pacouret, S., Shah, S., Comander, J. I., Kim, L. A., Lim, L., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.154 · Cited by 63
Hariri, A. H., Velaga, S. B., Girach, A., Ip, M. S., Le, P. V., Lam, B. L., Fischer, M. D., Sankila, E., Pennesi, M. E., Holz, F. G., et al. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.05.002 · Cited by 64
Self-citationLiquid Metal–Polymer Conductor-Based Conformal Cyborg Devices
Qi, J., Yang, S., Jiang, Y., Cheng, J., Wang, S., Rao, Q., & Jiang, X. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00317 · Cited by 66
Multimodal Imaging of Photoreceptor Structure in Choroideremia
Sun, L. W., Johnson, R. D., Williams, V. V., Summerfelt, P., Dubra, A., Weinberg, D. V., Stepien, K. E., Fishman, G. A., & Carroll, J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167526 · Cited by 64
CLINICAL PROGRESS IN INHERITED RETINAL DEGENERATIONS
Hafler, B. P. (2016) · Retina · doi:10.1097/iae.0000000000001341 · Cited by 64
Morales, M. U., Saker, S., Wilde, C., Pellizzari, C., Pallikaris, A. I., Notaroberto, N., Rubinstein, M., Rui, C., Limoli, P. G., Smolek, M. K., et al. (2016) · Translational Vision Science & Technology · doi:10.1167/tvst.5.6.6 · Cited by 63
Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases
Singh, K., Sethi, P., Datta, S., Chaudhary, J. S., Kumar, S., Jain, D., Gupta, J. K., Kumar, S., Guru, A., & Panda, S. P. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102321 · Cited by 64
Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments
Mitsios, A., Dubis, A. M., & Moosajee, M. (2018) · Therapeutic Advances in Ophthalmology · doi:10.1177/2515841418817490 · Cited by 62
Evaluation of an optimized injection system for retinal gene therapy in human patients
Fischer, M. D., Hickey, D. G., Singh, M. S., & MacLaren, R. E. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.086 · Cited by 61
Self-citationFuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61
Leroy, B. P., Birch, D. G., Duncan, J. L., Lam, B. L., Koenekoop, R. K., Porto, F. B. O., Russell, S. R., & Girach, A. (2021) · Retina · doi:10.1097/iae.0000000000003133 · Cited by 67
Optogenetic Therapy for Visual Restoration
Sakai, D., Tomita, H., & Maeda, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315041 · Cited by 62
Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy
Sauer, L., Andersen, K. M., Dysli, C., Zinkernagel, M. S., Bernstein, P. S., & Hammer, M. (2018) · Journal of Biomedical Optics · doi:10.1117/1.jbo.23.9.091415 · Cited by 61
Zhang, W., Li, L., Su, Q., Gao, G., & Khanna, H. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.049 · Cited by 60
Lacy, G. D., Abalem, M. F., Andrews, C., Popova, L., Santos, E. P., Yu, G., Rakine, H. Y., Baig, N., Ehrlich, J. R., Fahim, A. T., et al. (2020) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2020.08.032 · Cited by 61
Patrício, M. I., Barnard, A. R., Orlans, H. O., McClements, M. E., & MacLaren, R. E. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2016.12.006 · Cited by 59
Self-citationGene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) VectorPreprint
Barnard, A. R., Groppe, M., & MacLaren, R. E. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017293 · Cited by 62
Self-citationSubretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trial
MacLaren, R. E., Fischer, M. D., Gow, J. A., Lam, B. L., Sankila, E.-M. K., Girach, A., Panda, S., Yoon, D., Zhao, G., & Pennesi, M. E. (2023) · Nature Medicine · doi:10.1038/s41591-023-02520-3 · Cited by 58
Self-citationContemporary approaches to visual prostheses
Mirochnik, R. M., & Pezaris, J. S. (2019) · Military Medical Research · doi:10.1186/s40779-019-0206-9 · Cited by 58
Petersen‐Jones, S. M., Occelli, L. M., Winkler, P. A., Lee, W., Sparrow, J. R., Tsukikawa, M., Boye, S. L., Chiodo, V. A., Capasso, J. E., Bećirović, E., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci95161 · Cited by 56
Ramlogan‐Steel, C. A., Murali, A., Andrzejewski, S., Dhungel, B. P., Steel, J. C., & Layton, C. J. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13416 · Cited by 60
Development of Highly Efficient Dual‐AAV Split Adenosine Base Editor for In Vivo Gene Therapy
Chen, Y., Zhi, S., Liu, W., Wen, J., Hu, S., Cao, T., Sun, H., Li, Y., Huang, L. T., Liu, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000309 · Cited by 57
Materials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 57
Chien, Y., Hsiao, Y., Chou, S., Lin, T.-Y., Yarmishyn, A. A., Lai, W., Lee, M., Lin, Y., Lin, T.-W., Hwang, D., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01717-x · Cited by 59
Hohman, T. C. (2016) · Handbook of Experimental Pharmacology · doi:10.1007/164_2016_91 · Cited by 56
Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
Reul, J., Frisch, J., Engeland, C. E., Thalheimer, F. B., Hartmann, J., Ungerechts, G., & Buchholz, C. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00052 · Cited by 56
A User's Guide to the Inverted Terminal Repeats of Adeno-Associated Virus
Wilmott, P., Lisowski, L., Alexander, I. E., & Logan, G. J. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.276 · Cited by 59
Quantitative progression of retinitis pigmentosa by optical coherence tomography angiography
Jauregui, R., Park, K. S., Duong, J., Mahajan, V. B., & Tsang, S. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-31488-1 · Cited by 55
Gregori, N. Z., Lam, B. L., & Davis, J. L. (2019) · Retina · doi:10.1097/iae.0000000000001646 · Cited by 54
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
Wu, Y. F., Mao, W. F., Zhou, Y. L., Wang, X. T., Liu, P. Y., & Tang, J. B. (2015) · Gene Therapy · doi:10.1038/gt.2015.97 · Cited by 54
The Future Looks Brighter After 25 Years of Retinal Gene Therapy
Auricchio, A., Smith, A. J., & Ali, R. R. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.164 · Cited by 53
Controlled release strategies for rAAV-mediated gene delivery
Rey‐Rico, A., & Cucchiarini, M. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.10.015 · Cited by 52
Gene Transfer Properties and Structural Modeling of Human Stem Cell-derived AAV
Smith, L. J., Ul-Hasan, T., Carvaines, S. K., Van Vliet, K., Yang, E., Wong, K. K., Agbandje-McKenna, M., & Chatterjee, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.107 · Cited by 51
Has retinal gene therapy come of age? From bench to bedside and back to bench
Trapani, I., & Auricchio, A. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz130 · Cited by 55
Reid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 49
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Self-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Simunovic, M. P., Xue, K., Jolly, J. K., & MacLaren, R. E. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5630 · Cited by 50
Self-citationChandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Self-citation
Metadata
- Authors
- MacLaren, R. E., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Seymour, L., Clark, K. R., During, M. J., Cremers, F. P. M., Black, G. C. M., Lotery, A. J., Downes, S. M., Webster, A. R., & Seabra, M. C.
- Affiliations
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Oxford (GB)
- NIHR Oxford Biomedical Research Centre (GB)
- Imperial College London (GB)
- Nationwide Children's Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Radboud University Nijmegen (NL)
- Manchester Academic Health Science Centre (GB)
- University of Southampton (GB)
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2014-03
- Volume
- 383
- Issue
- 9923
- Pages
- 1129-1137
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4171740
- OpenAlex
- W2126115955
- Cited by
- 796
- References
- 28
- Citations by year
- 2026: 24 · 2025: 29 · 2024: 46 · 2023: 42 · 2022: 37 · 2021: 62 · 2020: 68 · 2019: 78 · 2018: 85 · 2017: 109 · 2016: 80 · 2015: 83 · 2014: 51
- FWCI
- 44.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Wellcome Trust (091984)
- Cancer Research UK (11339)
- National Institute for Health and Care Research (NF-SI-0509-10185)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- choroideremia, retinal gene therapy, adeno-associated virus vectors, Rab escort protein 1, CHM gene, X-linked retinal degeneration, visual acuity improvement, retinal sensitivity, microperimetry, retinal detachment, vector dose, rod and cone function, retinal pigment epithelium, eccentric fixation, blindness treatment
- MeSH terms
- Adenoviridae, Adult, Aged, Fluorescence, Genetic Vectors, Humans, Male, Middle Aged, Retinal Detachment, Visual Acuity, Genetic Therapy, Choroideremia, Gene Transfer Techniques, Transgenes, Adaptor Proteins, Signal Transducing, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
